Full-Time
Posted on 1/15/2025
Develops targeted radiation therapies for cancer
No salary listed
Senior
Remote in USA
Remote position available for candidates based in the USA.
Telix Pharmaceuticals develops and sells therapeutic and diagnostic products that use targeted radiation to improve the diagnosis and treatment of cancer and rare diseases. Their products work by delivering precise radiation to affected areas, which helps healthcare providers make better treatment decisions and offers personalized therapy options for patients. Unlike many other biopharmaceutical companies, Telix focuses specifically on areas such as urologic oncology, neuro-oncology, musculoskeletal oncology, and bone marrow conditioning, addressing significant unmet medical needs in these fields. The company's goal is to enhance patient care while maintaining a commitment to sustainability and ethical practices, ensuring that they create value for patients, shareholders, and employees.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Melbourne, Australia
Founded
2015
Help us improve and share your feedback! Did you find this helpful?
Annual Performance Bonus
Equity-Based Incentive Program
Paid Vacation
Paid Wellness Days
Hybrid Work Options
Remote Work Options
MELBOURNE, Australia, Feb. 26, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its breakthrough investigational kidney cancer PET[1] imaging agent TLX250-CDx (Zircaix®[2], 89Zr-DFO-girentuximab), granted a Priority Review and provided a PDUFA[3] date of 27 August 2025, paving the way for a U.S. commercial launch in 2025.If approved, TLX250-CDx will become the first commercially available imaging agent to accurately and non-invasively diagnose and characterize clear cell renal cell carcinoma (ccRCC), the most common and one of the most aggressive sub-types of kidney cancer. It works by specifically binding to carbonic anhydrase IX (CAIX), a validated target protein expressed on 95% of ccRCC cells to produce images with high tumor-to-background ratio and high intra- and inter-reader consistency.The BLA is based on Telix's successful global Phase 3 ZIRCON[4] study, which demonstrated a sensitivity of 86%, specificity of 87% and a positive predictive value (PPV) of 93% for ccRCC, including in very small, difficult-to-detect lesions[5]. The results of this study were published in The Lancet Oncology in September 2024, in a peer-reviewed manuscript by Professor Brian Shuch (University of California, Los Angeles, UCLA) and colleagues[6]. The paper outlines the critical unmet need for a new, non-invasive technique that can accurately detect and differentiate ccRCC from other renal masses in patients and concluded that TLX250-CDx meets this need and 'has the potential to be practice changing.'Kevin Richardson, Chief Executive Officer, Precision Medicine, said, "We are delighted that the FDA has accepted this BLA as it moves us one step closer to bringing our breakthrough product to patients
Telix to showcase urology pipeline at upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025).
MELBOURNE, Australia, Feb. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection).Illuccix is indicated in the UK for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, using PET. PSMA-PET imaging[2] represents a major advancement in prostate cancer management, largely replacing conventional imaging methods (bone scan, CT[3] scan) as the standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease and evaluation of BCR/biochemical persistence (BCP)[4].Gary Cook, MD, Professor of Molecular Imaging at Kings College London School of Biomedical Engineering & Imaging Sciences, commented, "PSMA-PET supply shortages in the UK and Europe have escalated over the past 12 months as demand increases, which has led to delays for men in urgent need of a scan to direct clinical management. It is great news that Telix can now help address this unmet need and improve equity of access in the UK through their Illuccix imaging agent and network distribution model."Raphaël Ortiz, Chief Executive Officer, Telix International added, "PSMA-PET imaging is one of the most important developments in prostate cancer detection in recent years and we are delighted that we can now bring Illuccix to physicians and their patients across the UK. A key advantage of Illuccix is that the radioisotope (gallium-68) can be produced using a generator locally, taking just a few minutes with minimal equipment
ImaginAb, Inc. has agreed to sell its next-generation therapeutic candidates, biologics technology platform, and research facility to Telix Pharmaceuticals. Post-transaction, ImaginAb will focus on its CD8 ImmunoPET, in Phase 2 trials, and its prostate cancer imaging agent. The sale allows Telix to explore new disease areas with radiotherapeutic technology. Jefferies LLC and Stifel, Nicolaus & Company advised on the transaction.
MELBOURNE, Australia and LIÈGE, Belgium, Jan. 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection), which was submitted in Europe via a decentralized procedure (DCP). This significant milestone follows the issuance of the Final Assessment Report from the German Competent Authority BfArM[2] as Reference Member State (RMS). Through the DCP, the RMS and all 18 European Economic Area (EEA) Concerned Member States (CMS)[3] agree that Illuccix should receive marketing authorization. The DCP regulatory process will now transition into an administrative national phase to implement authorizations to facilitate commercial launch in each country[4]. Kevin Richardson, Chief Executive Officer, Telix Precision Medicine commented, "We are delighted by this positive outcome, setting the stage for a European commercial launch of Illuccix